Correlation Engine 2.0
Clear Search sequence regions


  • adult (1)
  • child (1)
  • children (1)
  • female (1)
  • fiber (4)
  • humans (1)
  • infant (2)
  • layer (3)
  • patients (3)
  • spasms (1)
  • vigabatrin (14)
  • visual field (6)
  • visual field defects (10)
  • Sizes of these terms reflect their relevance to your search.

    To investigate the prevalence of vigabatrin-attributed visual field defect (VAVFD) in infantile spasms and the utility of optical coherence tomography (OCT) in detecting vigabatrin-related damage. We examined visual fields by Goldmann or Octopus perimetry and the thickness of peripapillary retinal nerve fiber layer (RNFL) with spectral-domain OCT at school age or adolescence. Out of 88 patients (38 females, mean age at study 15y, SD 4y 3mo, range 6y 4mo-23y 3mo [n=65] or deceased [n=21] or moved abroad [n=2]) exposed to vigabatrin in infancy, 28 were able to perform formal visual field testing. Two had visual field defect from structural causes. We found mild VAVFD in four patients and severe VAVFD in one patient. Median vigabatrin treatment duration for those with normal visual field was 11 months compared to 19 months for those with VAVFD (p=0.04). OCT showed concomitant attenuated RNFL in three children with VAVFD, and was normal in one. The temporal half of the peripapillary RNFL was significantly thinner in the VAVFD group compared to the normal visual field group. The overall prevalence of VAVFD is lower after exposure in infancy compared to 52% which has been reported after exposure in adulthood. The risk increases with longer treatment duration. Further studies should identify infants particularly susceptible to VAVFD and clarify the role of OCT. © 2021 Mac Keith Press.

    Citation

    Henna Jonsson, Mikko Lehto, Sampsa Vanhatalo, Eija Gaily, Tarja Linnankivi. Visual field defects after vigabatrin treatment during infancy: retrospective population-based study. Developmental medicine and child neurology. 2022 May;64(5):641-648

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 34716587

    View Full Text